Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization

Launched by BEIJING HOSPITAL · Jan 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called choroidal neovascularization (CNV), which is a serious eye problem that can lead to blindness. CNV happens when new blood vessels grow in the eye, which can leak and cause vision loss. The researchers want to learn more about how well a certain treatment, called anti-VEGF therapy, works for patients with CNV. They will use advanced imaging technology to look at the blood vessels in the eye before and after treatment to see how they change and to determine if these changes can predict how well a patient’s vision will improve.

To participate in this study, you must be over 18 years old and have active CNV, which means there must be signs of leaking vessels or fluid in your eye. You should also have a history of receiving anti-VEGF treatment and have at least three months of follow-up data available. However, you won’t be able to join if you have other serious eye diseases, have had recent eye surgery, or cannot complete the necessary eye exams. If you choose to participate, you can expect to undergo some imaging tests to help the researchers gather important information about your condition and the treatment’s effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>18 years old
• • Active choroidal neovascularization (activity criteria: blood vessel leakage confirmed by FFA, or subretinal fluid accumulation or bleeding seen by OCT)
• • History of anti-VEGF drug therapy
• • At least 3 months of follow-up data.
• Exclusion Criteria:
• • Unable to complete the examination due to severe cataract or vitreous hemorrhage
• • Any retinal diseases except choroidal neovascularization, such as multifocal choroiditis, diabetic retinopathy
• • History of intraocular surgery